Separately, HC Wainwright lifted their price objective on Capricor Therapeutics from $18.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday, October 4th.
Capricor Therapeutics Trading Down 2.3 %
Institutional Trading of Capricor Therapeutics
Large investors have recently made changes to their positions in the company. Morgan Stanley boosted its stake in Capricor Therapeutics by 7.4% during the 4th quarter. Morgan Stanley now owns 42,652 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 2,950 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of Capricor Therapeutics by 17.8% in the 4th quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company’s stock worth $76,000 after buying an additional 3,001 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Capricor Therapeutics by 39.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,236 shares of the biotechnology company’s stock worth $58,000 after buying an additional 3,466 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 226,110 shares of the biotechnology company’s stock worth $872,000 after purchasing an additional 4,077 shares during the period. Finally, State Street Corp raised its holdings in shares of Capricor Therapeutics by 10.4% in the 1st quarter. State Street Corp now owns 79,224 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 7,476 shares during the period. 10.18% of the stock is currently owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
- Five stocks we like better than Capricor Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- The most upgraded stocks in November have two things in common
- Retail Stocks Investing, Explained
- Monday.com rocked earnings like it’s the weekend
- What is the Hang Seng index?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.